Full Text View
Tabular View
No Study Results Posted
Related Studies
4-Aminopyridine in Episodic Ataxia Type 2 (4AP in EA2)
This study is enrolling participants by invitation only.
Study NCT01543750   Information provided by University of California, Los Angeles

First Received on May 27, 2011.   Last Updated on February 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Episodic Ataxia Type 2
Additional conditions recognized in this trial
Ataxia
Nystagmus, Pathologic
Spinocerebellar Ataxias
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Cerebellar Ataxia
Cerebellar Diseases
Cranial Nerve Diseases
Dyskinesias
Eye Diseases
Genetic Diseases, Inborn
Heredodegenerative Disorders, Nervous System
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Ocular Motility Disorders
Signs and Symptoms
Spinal Cord Diseases
Spinocerebellar Degenerations
Interventions listed in this trial
4AP
Placebo
Additional drug interventions recognized in this trial
4-Aminopyridine
More general drug interventions related to this trial
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Potassium Channel Blockers
Therapeutic Uses
Sponsors listed in this trial
University of California, Los Angeles
University of Rochester
University of South Florida


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services